Armata Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Armata Pharmaceuticals, Inc. (NYSE American: ARMP) on September 14, 2026. The report discloses a material regulatory milestone regarding the Company's clinical development pipeline.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory announcement and does not contain financial statements or operational metrics.
Material Changes
On September 14, 2026, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to the Company's product candidate AP-SA02. Key details include:
- Product: AP-SA02, an intravenously administered multi-phage product targeting Staphylococcus aureus (S. aureus).
- Indication: Adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard regulatory disclosure language. The press release associated with this announcement is furnished as Exhibit 99.1 but is not incorporated by reference into this filing.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed clinical context regarding the Breakthrough Therapy designation.
- Confirm the specific clinical trial phase and patient population for AP-SA02 in the Company's most recent periodic reports (10-K or 10-Q).
- Review the Company's cash position and burn rate in recent filings to assess runway for continued development of AP-SA02.
- Monitor subsequent filings for any updates on the FDA's review timeline or potential partnership opportunities related to this designation.